Saltar al contenido

PDS Biotechnology Corp (PDSB) stock: revenue, earnings & dividend

PDS Biotechnology Corp (PDSB, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener PDSB · Nasdaq Pharma & Biotech US-NJ

Key figures

Fiscal year
2025
Revenue
–
Revenue growth
–
Revenue growth 5y (p.a.)
–
Net income
-34.5 m $
Net margin
–
Operating margin
–
Earnings per share (diluted)
-0.74 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
30.5 m $
Equity
9.25 m $
Equity ratio
30.3 %
Return on equity
-372.9 %
Cash
26.7 m $
Operating cash flow
-27.75 m $
Free cash flow
-27.75 m $
Shares outstanding
105,005,429

History

Revenue by fiscal year

Net income by fiscal year

2016 -38.82 m $
2017 -50.86 m $
2018 -3.84 m $
2019 -7 m $
2020 -14.85 m $
2021 -16.92 m $
2022 -40.85 m $
2023 -42.94 m $
2024 -37.61 m $
2025 -34.5 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
2025–-34.5 m $-0.74 $–-27.75 m $
2024–-37.61 m $-1.03 $–-35.03 m $
2023–-42.94 m $-1.39 $–-33.64 m $
2022–-40.85 m $-1.43 $–-25.71 m $
2021–-16.92 m $-0.66 $–-12.49 m $
2020–-14.85 m $-0.89 $–-13.15 m $
2019–-7 m $––-18.07 m $
2018–-3.84 m $––-1.57 m $
2017–-50.86 m $––-40.7 m $
2016–-38.82 m $––-32.19 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)